postsurgical radiation and the subsequent administration of chemotherapy. e present-day neurosurgical treatment of a glioblast involves removing the maximum amount of malignant tumor tissue without involving critical areas of the brain that if resected would result in a serious postoperative neurological defect.
Radiation
Following surgical excision of a glioblast in which complete or incomplete removal of the tumor has been performed; the malignant tumor bed and surrounding brain areas receive conventional radiation therapy often in 30 treatments of radiation in a cumulative dosage of 60 gy. Additional radiation may be applied to other areas of the brain by directing multiple beams of radiation to specific brain locations; however, there is the possibility that additional radiation can be harmful to brain tissue. Furthermore, it does not appear that increased radiation therapy for a glioblast will have a significant influence on future survival statistics for this tumor.
Chemotherapy
If there is to be improvement in the poor statistics associated with a glioblast, it seems likely that chemotherapy will be a major factor in the treatment. e chemotherapeutic agents needed for effective destruction of malignant tumor cells will require easy access into brain tissue over an indefinite period of time.
e ultimate question is can the present-day treatment of a glioblast by surgery, radiation therapy, and chemotherapy be improved? ere appears to be a possibility that this can be accomplished.
An Interventional proposal
e initial procedure over the years for the treatment of a glioblast has been the surgical removal of the primary tumor and as much as possible of infiltrating malignant tissue surrounding the primary tumor. Success of this procedure has been limited by tumor tissue present in, or adjacent to, a critical brain area, a problem that has remained unresolved.
A recent article suggested that "there does not presently appear to be surgical techniques that would increase patients' survival rates following the excision of a primary glioblastoma WHO IV. " [1] is statement must be corrected since there are now two relatively new neurosurgical procedures that have the potential to improve the treatment outcome of patients with a glioblast.
THERAPEUTIC SOLUTION

5-Aminovolumic acid (ALA)
One of the new procedures that have the potential to improve the progression-free period that follows the initial resection of glioblast is the intraoperative utilization of the drug 5-ALA. is drug was first described in 1983 and was approved for glioblast treatment by the FDA on July 3, 2017. Recently, the first 5-ALA fluorescence-guided brain tumor surgery symposium was held in the USA at the Mount Sinai Hospital in New York City on November 20, 2018. [17] [18] [19] [20] [21] [22] [23] 5-ALA, when administered 3 h before surgery for a glioblast, results in the fluorescence of malignant tissue within the brain. At the time of surgery, the drug causes a distinct red coloration in malignant brain tissue predominantly around the area of the primary tumor. e distinct red coloration loses its intensity at the site of a primary malignant tumor with the fluorescent red coloration decreasing to pink at the margin of the lesion. Fluorescence-guided surgery enables neurosurgeons to distinguish tissue infiltrated by malignant cells from normal brain tissue. e red and pink coloration of malignant tumor at the margin of a tumor resection allows for a more complete resection of malignant brain tissue. e visual distinction observed between normal and malignant tissue at the time of surgery can result in the surgical removal of a greater amount of malignant brain tissue than was previously possible. Fluorescence-guided surgery has made this achievable.
e amount of 5-ALA that is necessary for fluorescence has been proposed at a dosage level of 5, 10, and 20 mg/kg. e optimal dosage of the drug is presently being investigated by various studies which undoubtedly will be significant.
Omentum
A second new neurosurgical procedure that may improve the survival statistics of a glioblast is the use of the omentum. It has been shown over the past several decades that when an intact vascularized omental pedicle is placed directly on the brain of animals [3, 4] and humans, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] blood vessels from the omentum penetrate directly and deeply into the underlying brain. e inner lining in these omental blood vessels is completely free of cellular material. [2] In contrast, in the normal brain, blood-brain barrier (BBB vessels) contains strongly compacted endothelial cells that line the inside of the blood vessel, which prevent unwanted material, including particular chemotherapeutic agents, from entering the brain. [16] Chemotherapeutic agents flowing through omental blood vessels will have the potential to freely pass through the wall of an omental blood vessel and perfuse throughout the entire brain as shown in Figure 1 .
Omental blood flow studies have shown that placing the omentum on the brain of humans allows for increased blood flow throughout the entire brain. [6] e blood flow through these omental vessels would be expected to allow chemotherapeutic agents to perfuse the brain and, most importantly, to come in contact with glioblast cells present throughout the brain. e postsurgical contribution of 5-ALA and the subsequent placement of the omentum on the brain of patients with a glioblast raise the possibility and the hope that the combination of 5-ALA and the omentum may improve the survival statistics of a glioblast.
CONCLUSION
Due to the BBB that limits the entrance of possible effective chemotherapeutic agents into the brain infiltrated by glioblast cells, there has been no appreciable improvement in the survival statistics of this tumor since the endeavor of Harvey Cushing over a century ago. Fluorescent-guided surgery now aides in identifying undetected malignant brain tissue that previously was not observed, an achievement that was impossible before the introduction of 5-ALA. e combination of 5-ALA and the placement of the omentum on the brain harboring glioblast cells may have the potential to improve the survival statistics of this tumor.
e ongoing surgical evaluation of 5-ALA combined with the use of the omentum in the treatment of a glioblast would appear to justify the undertaking of clinical trials pertaining to 5-ALA and the omentum in the possibility that these two factors may improve the future survival statistics of patients with a glioblastoma multiforme WHO IV.
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